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ABSTRACT 
Small cell lung cancer (SCLC) is an aggressive form of cancer with 5-year 
survival rate and poor prognosis. Since patients` initial response to therapy 
is rapidly followed by a relapse with the drug-resistant disease, new thera-
pies are required. The aim was to evaluate whether H146 cell line tumor was 
able to maintain the morphological pattern when grafted on the chicken 
embryo chorioallantoic membrane (CAM). Also, to evaluate the morpho-
logical changes in the CAM after grafting the tumor without or with treat-
ment with sodium valproate (NaVP). The cell culture of the commercial NCI-
H146 cell line was used for the formation of the tumor. The tumor of 1x106 
cells and I type rat tail collagen was dropped onto the absordable sponge and 
instantly grafted on CAM. After 5 days of incubation chicken embryos were 
sacrificed and CAMs were cut out. Standard H&E staining and immunohisto-
chemistry (CD56) were performed. The histomorphometrical analysis of 
non-treated (n=5), 4 mM NaVP-treated (n=5) and 8 mM (n=5) of NaVP-
treated groups was performed. The thickness of the CAM was measured in 
all the investigated groups in the areas under the onplant and in the neigh-
bouring sites. H146 cells are able to maintain morphological appearance 
on the CAM and retained the expression of specific profile for CD56. H146 
cell tumor increased the thickness of the CAM under the tumor in the non-
treated group (509.2±184μm). After treatment with 4 mM and 8 mM of NaVP 
CAM thickness decreased (362±232.6 μm and 147.8±98.4 μm respectively; 
p<0.0001). The effect of NaVP on CAM increased with increasing  solution 
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concentrations of 4 mM and 8 mM. CAM thickness in the non-treated group 
 neighbouring to the tumor site was 139.1±138.4 μm, in 4 mM NaVP-treated 
group – 104.9±81 μm and in 8 mM NaVP-treated group CAM thickness 
reached only 70.8±51.5 μm. CAM thickness in the non-treated group signifi-
cantly differs compared to 4 mM and 8 mM of NaVP – the treated groups 
(p<0.05, p<0.0001). Difference between both NaVP-treated groups is also 
significant (p<0.05). CAM is a suitable model for in vivo analysis of human 
H146 cell line formed tumor. Cells grafted on the CAM preserved their mor-
phology and expressed characteristic immunohistochemical markers. CAM 
mesenchyme proliferation was suppressed under the influence of NaVP in 
concentration–dependent manner.
Key words: chicken embryo; chorioallantoic membrane; small cell lung cancer; 
sodium valproate
INTRODUCTION
Lung cancer, including small cell lung cancer (SCLC), is a leading cause of 
cancer related death, both in the USA and worldwide. SCLC composes 16% 
of all lung cancers and causes signifi cant morbidity and mortality worldwide. 
It tends to metastasize outside the chest two-thirds of the time at clinical 
 presentation, and approximately only 7% of patients are alive for 5 years since 
the beginning of treatment [20]. Recently, new agents such as erlotinib and 
bevacizuman, have been approved for the treatment of lung cancer, however the 
5-year survival rate reaching 16% still remains the same [6]. On the contrary 
to other agents targeting single gene product, epigenetic drugs have chromatin 
as their target through the inhibition of histone deacetylases (HDAC’S) and 
DNA methyltransferases (DNMT’S) therefore, they may act upon most or all 
tumor types [4]. Because small cell lung carcinomas are reff ered as neuroen-
docrine malignancy [17], for these reasons in our study we used MAb 123C3 
for the immunohistochemical staining of SCLC which was tested on paraffi  n 
sections. CD56 or neural cell adhesion molecule (NCAM) comprises a family 
of cell surface sialoglycoproteins of the immunoglobulin superfamily. NCAM 
is expressed mainly in natural killer (NK) cells, NK-like T cells, neuroecto-
dermal/neuroendocrine tissues, and their corresponding neoplasms [7].
Valproic acid sodium salt (NaVP), a well-known anticonvulsive agent, in 
1997 emerged as an antineoplastic agent as well, when fi ndings suggested the 
substance being able to inhibit proliferation and induced the diff erentiation 
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of primitive neuroectodermal tumor cells in vivo [1]. In particular valproic 
acid is an inhibitor of HDAC’s displaying appropriate pharmacokinetic proper-
ties, and yielding only moderate toxicity that is acceptable in the context of an 
anticancer treatment [5]. Nowadays NaVP approaches an increasing interest. 
Several studies have shown antitumoral activities, as well as anti-angiogenic 
properties of NaVP, either alone or in combination with standard anticancer 
treatment [2, 5, 10–11, 14–15, 18, 22].
Since dose-response determination, toxicity and schedule (i.e. doses, 
timing) require a substantial number of animals, the chick embryo chorioal-
lantoic membrane (CAM) model is used in the pharmaceutical research for 
the evaluation of drug delivery systems, as well as tumor growth and metas-
tasis. Histologically the CAM consists of two epithelial sheets that limit a thin 
layer of stroma. Th e highly vascularized network of the CAM sustains tumor 
viability, which have been shown to engraft  and follow all the steps of tumor 
progression: growth, angiogenesis, invasion, extravasation and metastasis 
[3, 21]. Th is alternate model suggests that primary xenograft s models may 
represent a better platform for preclinical therapeutic testing.
We investigated the capacity of SCLC cell line NCI-H146 to maintain its 
proliferative and metastatic capacity in vivo, the ability to form a solid tumor 
on CAM while being aff ected with concentrations of either 4 mM or 8 mM of 
NaVP compared to non-NaVP-treated group. We evaluated whether NCI-H146 
cells are able to retain their original morphological characteristic when graft ed 
on the CAM including the ability to penetrate the deeper layers of the CAM 
under the infl uence of valproic acid and the thickness of the CAM aft er the 
malignant cell transplant of the tumor which was not treated with NaVP and 
tumors which was treated with increasing doses of NaVP.
MATERIAL AND METHODS
Cell culture. Human SCLC NCI-H146 cells were obtained from the State 
Research Institute Centre for Innovative Medicine (Vilnius, Lithuania). Th e 
H146 cells were maintained in RPMI 1640 medium supplemented with 4.5g/L 
glucose, 2 mM L-glutamine, sodium pyruvate, HEPES and contained 10% 
heat-inactivated FBS, 100 U/ml penicillin and 100 μg/ml streptomycin were 
also added. Cells were grown at 37oC in a humidifi ed atmosphere of 95% air 
and 5% CO2.
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Tumor xenograft  model. Cells were mixed with the solution of concentration 
equivalent to 4mM and 8 mM of NaVP (SigmaAldrich; Merck KGaA) and type 
I rat tail collagen (GIBCO, USA) to a fi nal concentration of 1×106 cells/20 μl. 
Tumors without NaVP, were formed only of H146 cells and type I rat tail 
collagen in a total volume of 20 μl containing the same amount of cells. NaVP 
was dissolved in the serum-free RPMI-1640 medium. 20 μl of liquefi ed tumor 
was pipetted on an absordable sponge. Formed tumor was then placed on a 
CAM between a major blood vessels. Tumors were further visualized under 
the stereomicroscope (SZX16, Olympus, Japan) from the 2nd to the 5th day of 
tumor graft ing (9th– 12thday of embryo day development (EDD)) consecutively.
Preparation of the CAM. Fertilized Cobb 500 chicken eggs from a local 
hatchery were transferred into a hatching incubator (Maino Enrico, 0084 AXH, 
Oltrona, Italy). Relative air humidity was set of 60% and a temperature of 37°C. 
Eggs were automatically rotated until EDD 3. On EDD 3 a small hole at the air 
chamber was drilled and approximately 2 ml of albumin was removed. Th en 
a window of approximately 1 cm in diameter was opened in the eggshell and 
covered with a sterile transparent tape. Th e eggs were then returned to the 
incubator and kept until harvesting the CAM.
CAM sampling. On EDD 12 chick embryos were sacrifi cied, the CAMs of all 
the investigated groups were cut out and embedded into paraffi  n, followed 
with further serial sectioning using LEICA RM 2155 microtome (Leica Micro-
systems, Inc., Buff alo Grove, IL, USA).
Hematoxylin-Eosin staining, cytological staining and immunohisto chemistry 
(IHC) with CD56. Standard hematoxylin and eosin (H&E) staining was 
performed. Cytological staining was performed using the standard  cytological 
smear technique. Cells were stained using Diff -Quik® Solutions (Medion Diag-
nostics, Dade Behring Inc.) by consecutive brief immersions for 5 seconds 
in each solution. Firstly cells were fi xed in methanol, then counterstained 
with Th iazine dye and Eosin Y. For immunohistocemistry tissue slides were 
placed in xylene, then into the ethanol of graded series (70%, 80% and 90%). 
Epitope retrieval was performed using a high pH epitope retrieval solution 
(Dako, USA) in a pressure cooker (110oC for 3 minutes). Peroxidase blocking 
solution (Dako REAL™, Dako, USA) was added followed by 20 wash buff er 
(Dako, USA). Th en the primary antibody solution (mouse Anti-CD56, 1:100, 
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clone: 123C3, Life Technologies, USA) was added for 1 h at room temperature. 
Aft erwards the secondary antibody was added (EnVision™ FLEX+ MOUSE 
(LINKER), Dako, USA) which was followed by the FLEX/HRP (EnVision™ 
FLEX/HRP, Dako), both with incubation for 30 minutes at room temperature. 
Later, 3.3’diaminobenzidine chromogen (Dako) was added. Finally slides were 
counterstained using Mayers’s hematoxylin and covered with cover slides using 
mounting media (Roti HistoKit). 
Histomorphometric analysis of the CAM. Th ickness of the CAM was  measured 
using an Olympus BX 40F4 microscope (Olympus Corporation, Tokyo, Japan) 
equipped with the XC30 digital camera (Olympus Corporation). A magnifi ca-
tion of x4 was used to evaluate the thickness of CAM under the onplant in a 
constant length of all the investigated groups. Th e histomorphometric  analysis 
was performed using the CellSens Dimension 2010 soft ware (version 1.3; 
Olympus Corporation).
Statistical analysis. Data are presented as mean±SD. Statistical signifi cance 
was calculated using the analysis of variance One-Way Anova using IBM SPSS 
statistics 23. Data were considered statistically signifi cant when p<0.05 or 
highly statistically signifi cant when p<0.0001.
RESULTS
H146 cell tumor retained its morphological characteristics and SCLC specifi c 
CD56 expression aft er graft ing on the CAM. Th e Histological analysis of 
hematoxylin and eosin staining of H146 cell line tumor formed on CAM 
revealed retained mitotic activity in vivo of SCLC compared to in vitro with 
enhanced metastasis into CAM’s mesenchyme layer. H146 cells are proved to 
be highly proliferative (mitotic cells, fi gure 1, A, arrows) and are seen migrating 
away from the main part of the tumor. Mitotic fi gures were also noticed in 
the cytological smears of H146 cell line (Figure 1, A). Immunohistochemical 
staining of SCLC xenograft s used in this study revealed maintained consistent 
expression of CD56 (Figure 2). Furthermore our results show a tumor which by 
its histologic features and tumor marker expression profi les closely resembles 
the parental tumor described by Kaufmann et al. [7]. SCLC tumor without 
NaVP treatment invading the mesenchyme is seen in Figure 2, where two main 
fi elds can be distinguished (Figure 2, B and C). Th e expression of CD56 in the 
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H146 cells appearing at the border of tumor and CAM’s mesenchyme became 
much more prominent (Figure 2, C) than the cells existing at the periphery of 
the tumor (Figure 2, B) which cytoplasm failed to retain the high expression 
of CD56. Th is result indicates the malignancy of SCLC cells and the need of 
nutrient supply for the tumor from the existing blood vessels in the mesen-
chyme layer. Migrating cells from the main part of the tumor to the mesen-
chyme are labelled by CD56 (Figure 2, D – arrows). 
Valproic acid reduces thickness of the CAM at the site of H146 cell tumor 
implantation. Th e thickness of the CAM was assessed in each group of non-
treated (n=5), 4mM NaVP-treated (n=5) and 8 mM NaVP-treated (n=5) 
tumors at the site of implantation and in the neighbouring sites. Statistically 
signifi cant results were noticed in the non-treated group compared to 4 mM 
NaVP-treated group (p<0.0001), where CAM thickness was reduced by 29%, 
while comparing the non-treated group. In 8 mM NaVP-treated group CAM 
thickness was signifi cantly reduced even by 72% (p<0.0001). Statistically 
 signifi cant results were also noticed between both treated groups of 4 mM 
and 8 mM of NaVP (p=0.002), where CAM thickness was reduced by 60% 
(Figure 3). Th e thickness of the CAM in non-treated, 4 mM NaVP-treated and 
8 mM NaVP-treated are 509.2±184 μm, 362±232.6 μm and 147.8±98.4 μm 
respectively.
Valproic acid reduces thickness of the CAM at the neighbouring site of H146 
cell tumor implantation. CAM thickness in the neighbouring sites away from 
the onplant in non-treated group is 139.1±138.4 μm, in 4 mM NaVP-treated 
group 104.9±81μm and in the 8 mM NaVP-treated group CAM thickness is 
only 70.8±51.5 μm. When comparing the non-treated group with 4 mM NaVP-
treated group statistical signifi cance is noticed (p<0.05), comparing groups 
of non-treated and of 8 mM NaVP-treated statistical signifi cance increases 
(p<0.0001) and the diff erence between each NaVP-treated group of 4 mM and 
8 mM is signifi cant (p<0.05, Figure 4).
Evaluation of Hematoxylin-Eosin stained H146 cell tumors on the CAMs. 
Figure 5 represents histological sections of all investigated groups – H146 
tumors without treatment (Figures 5A and 5B), tumor with 4 mM NaVP-
treated cells (Figure 5C), tumor of 8 mM NaVP-treated cells (Figure 5D). Th e 
highly vascularized tumor of large size of the non-treated group is shown in 
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Figure 1. H146 cells in cytological smear and in tumor formed on the CAM. Tumor of 
CAM on EDD 12 without treatment showing mitotically active H146 cells in histological 
section (B – arrows, C) likewise in cytological smear (A). Scale bar – 100 μm (A and B). 
Scale bar – 1 mm (C).
Figure 2. Migrating SCLC cells into the mesenchyme of the CAM. H146 cells show the 
 expression of the neuroendocrine marker CD56 (A, B, C and D). The expression of CD56 in 
H146 cells closer to the mesenchyme is higher (C) than those at the top of the tumor (B). 
The migrating cells escape from the main tumor area and metastatised deeper into the 
mesenchyme, H146 are labelled by arrows (D). Scale bar – 1 mm (A), 100 μm (B, C and D).
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Figure 3. CAM thickness under non-treated and 4 mM and 8 mM NaVP-treated tumors. 
CAM thickness (in μm) is highly reduced in 4 mM and 8 mM of NaVP solution treated 
tumors when comparing to non-treated H146 cell tumors. 
Figure 4. CAM thickness in the neighbouring area to non-treated and 4mM and 8mM 
NaVP-treated tumors. CAM thickness (in μm) is highly reduced in 4 mM and 8 mM of NaVP 
solution treated tumors when comparing to non-treated H146 cell tumors. 
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Figure 5. Hematoxylin and Eosin staining of CAMs with non-treated and 4 mM and 
8 mM NaVP-treated tumors on EDD 12. CAM with tumor made of non-treated cells 
(A and B) contains large amount of blood vessels in the tumour tissue (A, arrows), CAM is 
thickened under the tumor. C and D represents tumors on the CAMs made of 4 mM and 
8 mM NaVP-treated cells respectively. Decreased tumor volume is encircled with a dashed 
line (T). Scale bar – 1 mm.
Figures 5A and 5B, numerous small blood vessels are labelled with arrows. In 
Figure 5C CAM with tumor made of 4 mM NaVP-treated cells is shown with a 
notably lower amount of neoplastic tissue and slightly reduced thickness of the 
CAM, while Figure 5D represents CAM with the tumor made of 8 mM NaVP-
treated cells with much more reduced thickness of CAM and reduced mass of 
tumor inside the mesenchyme.
DISCUSSION
For a long time, the CAM has been used for the study of tumor growth and 
metastasis because the chick’s immune system is not fully developed untill 
EDD 18 and the conditions for rejection have not been yet established [16]. 
Korngold and Lipari demonstrated that the human tumor transplanted and 
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 re-transplanted on CAM retain and express human antigens aft er several 
passages [8]. Our study confi rmed this statement. We developed an experi-
mental tumor model for the human SCLC cell line (NCI-H146) and demon-
strated that the human SCLC cells implanted on the CAM formed vascularized 
tumors within 5 days. Tumor cells highly expressed markers specifi c for SCLC 
especially at the tumor implantation site. Drug delivery systems (DDS) are 
oft en studied in vitro with cells in culture and then tested in pre-clinical animal 
models [19]. However, a leap from in vitro studies with cells to in vivo pre-
clinical animal models usually leads to unsatisfactory results due to the high 
cost of the pre-clinical studies. Th us the CAM has been used as an excellent 
platform to test multiple DDS formulations as an intermediate step between in 
vitro analysis and in vivo preclinical evaluation in mammals [12]. Th e tumors 
aff ected with NaVP resulted in a highly decreased CAM thickness under the 
implantation site compared to the non-treated group as well as in the neigh-
bouring sites away from the main tumor tissue. Th e cells formed of treated with 
NaVP cells formed smaller tumors as well. Previous studies have shown in vitro 
eff ect of NaVP on the other SCLC cell line DMS53, when treatment with NaVP 
concentrations as low as 1 mM signifi cantly impaired the cell mitochondrial 
activity, while higher concentrations (6 mM – 10 mM) of NaVP resulted in 
the absence of tumor markers [15]. Similar results have been shown testing 
valproic acid on diff erent tumor cell lines other than SCLC. Masatoshi and 
co-authors showed a potential usefulness of NaVP in combination with radio-
therapy for treating oesophageal cancer [18]. Nowak-Sliwinska with collabora-
tors tested the eff ect of minimally invasive PDT (photodynamic therapy) that 
can potentially destroy the unwanted neoplastic tissue while sparing the neigh-
bouring normal tissue. It was noted that the PDT treatment induces wounding 
of the CAM tissue leading to a thinner membrane as compared to the untreated 
area [13]. Likewise our results show, CAM thickening was also seen in the 
prostate cancer cell inoculation [9]. Th us our fi ndings correlate with the results 
of other authors described above, indicating that NaVP changes proliferation 
of cancer cells graft ed on CAM further changing its morphologic appearance 
by decreasing the thickness at the site of onplant. In this well vascularized 
chorioallantoic membrane, the versatile system for in vivo cancer research, we 
achieved highly reliable diff erences in the thickness of the CAM of non-treated 
and NaVP-treated SCLC-CAM groups, possibly showing the anti-tumor and 
anti-angiogenic eff ect keeping cancer cells from active proliferation.
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